In this context, the demonstration by our group that such inhibitory receptors may be expressed also by CD8pos CTL, upon antigen or cytokine‐induced cell proliferation or exposure to TGF‐β, offered a clue for the important studies by Andrè et al of NKG2A blocking in tumor therapy. This evidence concerns the gene KLRC1 and neoplasm.